Company Description
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States.
The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor.
The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Robert Bitterman |
Contact Details
Address: 11 Apex Drive, Suite 300A Marlborough, Massachusetts 01752 United States | |
| Phone | 508 767 3861 |
| Website | phiopharma.com |
Stock Details
| Ticker Symbol | PHIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533040 |
| CUSIP Number | 71880W303 |
| ISIN Number | US71880W5013 |
| Employer ID | 45-3215903 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert J. Bitterman | President, Chief Executive Officer and Chairman |
| Lisa Carson | Principal Financial Officer, Principal Accounting Officer and Vice President of Finance and Administration |
| Linda M. Mahoney | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | SCHEDULE 13G/A | Filing |
| Aug 4, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 30, 2025 | ARS | Filing |
| Jul 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 30, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 7, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-K | Current Report |